MT. KISCO, N.Y., April 17, 2017 -- ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader in the development and marketing of OTC healthcare products, has been informed by OTC Markets Group the company will have until May 15, 2017 to file its Annual Report on Form 10K (prior to OTC Markets taking any action with respect to the company).
ImmuDyne currently expects to finalize its financial results and file its Annual Report on Form 10-K with the SEC as soon as practicable and further expects that the financial information contained in the Form 10-K will be consistent in all material respects with the financial results reported in our press release dated March 6, 2017. Based on the review and analysis conducted to date, no material adjustments, restatement or other revisions to previously issued financial statements of the Company are currently expected to be required.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. The Company's products include once a day oral intake capsules as well as topical serums and creams for skin application. lmmuDyne also has developed a proprietary natural delivery technology for potential new market opportunities. All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
Contact: ImmuDyne, Inc. Mark McLaughlin: +1-914-714-8901


Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
Google Secures Pentagon AI Deal for Classified Projects
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 



